Huons Group subsidiary Humedix launched its human tissue ‘Elravie Re2O’ to strengthen its aesthetic lineup.

Humedix Co., Ltd. (CEO Kim Jin-hwan) announced on the 18th that it recently signed a distribution contract with L&C Bio Co., Ltd. (CEO Lee Hwan-chul), a regenerative medicine company, to launch the product.

With this contract, Humedix has secured the domestic rights of dermatologists and clinics of human tissue Elravie Re2O. It aims to expand its beauty range in the beauty plastic surgery market following Dermashine and DermaAutom.

Elravie Re2O is the first human tissue to use cell-free allogeneic dermis (hADM). When applied to the skin, fundamental skin regeneration effects such as blemishes, blemishes and skin texture, and density improvement can be expected as well as pore improvement.

In addition, L&C Bio`s patented process, `Alloclean Technology`, human tissue processing technology, was applied. It is a technology that enhances safety by removing cells and immune rejection causes in tissues without damaging the tissue`s unique three-dimensional structure.

As it is the first cell-free alloma dermis product in the aesthetic market, we plan to secure academic data and promote it through academic societies, said Kim Jin-hwan, CEO of Humedix. "We will create a new wind in the aesthetic market in Korea by signing the Elravie Re2O business agreement."